Replies to Post #216632 onBiotech Values | InvestorsHub

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Replies to post #216632 on Biotech Values

Replies to #216632 on Biotech Values

05/10/18 9:09 AM

#218968 RE: JohnWayne #216632

EXEL -9%/PM on failed phase-3 in CRC:

https://finance.yahoo.com/news/exelixis-provides-imblaze370-phase-3-050100667.html

07/11/18 11:26 AM

#219997 RE: JohnWayne #216632

MRK—PDUFA for Keytruda-monotherapy sBLA in second-line HCC is 11/9/18 (with priority review):

https://www.businesswire.com/news/home/20180711005195/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-Biologics